Navigation Links
Is yakult helpful in the treatment of irritable bowel syndrome?
Date:9/9/2008

SIBO is a common feature in IBS and in fact may be directly related to the genesis of IBS symptoms. An ERBHAL on a lactulose breath test may indicate SIBO. Antibiotics and elemental diets have been shown to be effective in treating SIBO, but the efficacy of probiotics is untested. A pilot study was undertaken to determine the effect of L. strain Shirota (Yakult(R)) on intestinal fermentation patterns of IBS patients. After 6 week of treatment with 1 x 65 mL dose of Yakult(R) daily, 9 of 14 patients (64%) completing the study had reversal of ERBHAL, with the median time of first rise increasing from 45 to 75 min (P = 0.03). Furthermore, symptoms improved in those in whom ERBHAL was corrected. The results indicate that Yakult(R) alters fermentation patterns suggesting a reduction in SIBO. ERBHAL can also indicate rapid small intestinal transit and therefore, in order to confirm the effect of Yakult(R) on SIBO, future studies will include monitoring of transit time in addition to placebo control.

A research article to be published on August 28, 2008 in the World Journal of Gastroenterology addresses this question. The research team was led by Peter Gibson and his colleagues at Monash University, Box Hill Hospital. The pilot trial was undertaken to determine whether a probiotic could have an effect on SIBO. Currently, SIBO is managed by antibiotics and/or elemental diets, the side effects and practicalities of which make them undesirable options. Probiotics may provide a safe alternative. The results of the pilot trial warrant a well powered, double blind, placebo-controlled trial.

The effect of probiotics on SIBO had not previously been investigated, but after taking Yakult(R) daily for 6 wk, there was a significant shift in the time of first rise on the lactulose breath test indicating a reduction in SIBO. If these findings are confirmed by further research, Yakult(R) may be a safe and effective alternative for the management of this patient group.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related biology news :

1. Statin does not appear helpful for children with learning disabilities caused by genetic disorder
2. Study confirms that low-calorie sweeteners are helpful in weight control
3. Fish oil -- helpful or harmful?
4. Breastfeeding boost IQ in infants with helpful genetic variant
5. New once-a-week treatment for type 2 diabetes developed by Mount Sinai researcher
6. Landmark study opens door to new cancer, aging treatments
7. Common treatment to delay labor decreases preterm infants risk for cerebral palsy
8. UC Davis researchers define characteristics, treatment options for XXYY syndrome
9. Why a common treatment for prostate cancer ultimately fails
10. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
11. Childrens national co-leads nationwide study of landmark sickle cell treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology: